Last reviewed · How we verify
Debio 0123 and Sacituzumab govitecan — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Debio 0123 and Sacituzumab govitecan (Debio 0123 and Sacituzumab govitecan) — MedSIR.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Debio 0123 and Sacituzumab govitecan TARGET | Debio 0123 and Sacituzumab govitecan | MedSIR | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Debio 0123 and Sacituzumab govitecan CI watch — RSS
- Debio 0123 and Sacituzumab govitecan CI watch — Atom
- Debio 0123 and Sacituzumab govitecan CI watch — JSON
- Debio 0123 and Sacituzumab govitecan alone — RSS
Cite this brief
Drug Landscape (2026). Debio 0123 and Sacituzumab govitecan — Competitive Intelligence Brief. https://druglandscape.com/ci/debio-0123-and-sacituzumab-govitecan. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab